In contrast, the highly viremic pigs maintained a similar ADG (P < 0.55) during challenge having a fold change of 1.10 (wk 2), 0.94 (wk 3) and 1.09 (wk 4) compared to wk 1. Starting with wk 3 the individuals tend to form separate clusters based on their viral load and ADG.
The females received three injections of cabergoline every other day during 1 wk and further analyses started 2 wk after the end of the treatment (Supplemental Fig. 1, published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org).org
Individual feeding started 4 wk prior to the expected calving date and measurements were made until the end of the 8th wk of lactation.
Monensin was added to the concentrate starting either 2 wk before (293 cows) or 5 wk after calving (601 cows) for periods ranging 16 to 37 wk.
From wk 24 to wk 52, inhibition of radiographic progression was maintained for ustekinumab-treated patients, and progression was substantially reduced among initial placebo recipients who started ustekinumab at wk 16 or wk 24 (wk 24 – wk 52, total vdH-S score mean change: 0.08).
Tumor incidence and size were monitored starting from 1 wk after inoculation, once every other day.
Almost all BALB/c c-FLIPL Tg mice developed a generalized lymphadenopathy and splenomegaly starting from 3 wks of age and being evident by 6 10 wks of age, of which 20 30% BALB/c c-FLIPL Tg mice exhibited diarrhea.
Thus, ARR2PBCreER(T2)×Ptenfl/fl or Ptenfl/fl control mice were injected with OHT daily for 5 consecutive days starting at 6 wks of age and then sacrificed at either 4 10,16 20, or 30 40 wks p.i.
In this study, we first report that BALB/c c-FLIPL Tg mice spontaneously develop lupus-like disease starting from 3 4 wks of age, characterized by splenomegaly, lymphadenopathy, multi-organ infiltration including liver, lung, gastrointestine, heart, and salivary gland, proliferative glomerulonephritis with immune complex deposition, and high titers of auto-Abs.
Whole blood was collected from each patient at the following time points: 1) within 14 d prior to starting protocol therapy (baseline); 2) wk 3 4; 3) wk 9 10; wk 4 of maintenance cycles 1, 2, 3, and 6.
